TEE
CASI

Tibra Equities Europe’s CASI Pharmaceuticals CASI Stock Holding History

Tibra Equities Europe’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21,630
Closed -$335K – 67
2021
Q2 		$335K Buy
+21,630
New +$364K 0.1% 101

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Tibra Equities Europe's CASI Position: Q3 2021 in Review

Tibra Equities Europe sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 21,630 shares — an estimated $335K sold.

Tibra Equities Europe first reported a position in CASI in Q2 2021 and held it in 1 quarter. The position peaked at $335K in Q2 2021. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

  • Tibra Equities Europe reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 21,630 CASI Pharmaceuticals shares in Q3 2021, an estimated $335K.
  • Tibra Equities Europe first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's CASI Pharmaceuticals position peaked at $335K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.